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Abstract  
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. In the past 20 years, the canonical 
types of drugs used to treat ovarian cancer have not been replaced and the survival rates have not changed. 
These facts show the clear need to find new therapeutic strategies for this illness. Thus, the aim of the present 
study was to investigate the effect of a gamma-secretase inhibitor (DAPT) in combination with the Platelet-
derived growth factor B (PDGFB) on an ovarian cancer xenograft model. To achieve this goal, we analyzed the 
effect of the administration of DAPT alone and the co-administration of DAPT and recombinant PDGFB on 
parameters associated with tumour growth and angiogenesis in an orthotopic experimental model of ovarian 
cancer. We observed that the dose of DAPT used was ineffective to reduce ovarian tumour growth, but showed 
anticancer activity when co-administered with recombinant PDGFB. The administration of PDGFB alone 
normalized tumour vasculature by increasing periendothelial coverage and vascular functionality. Interestingly, 
this effect exerted by PDGFB was also observed in the presence of DAPT. Our findings suggest that PDGFB is 
able to improve tumor vascularity and allows the anticancer action of DAPT in the tumor. We propose that this 
therapeutic strategy could be a new tool for ovarian cancer treatment and deserves further studies. This article is 
protected by copyright. All rights reserved 
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Introduction 
In 2012, an estimated 239,000 women were diagnosed with ovarian cancer worldwide and 152,000 of them 
died of the disease (Ferlay J, 2013). Ovarian cancer has a high mortality rate and 69% of women with this 
illness will succumb to the disease (Lengyel, 2010). This is mainly due to a late detection because of the lack 
of symptoms, which implies that, at the time of the diagnosis, this cancer is in an advanced stage. The first step 
in treating most stages of ovarian cancer are surgery and chemotherapy, and a cure is expected if no cancer 
cells remain after initial therapy is completed. By contrast, in most patients, the recurrence is common if 
residual cancer cells are present after initial treatment (Narod, 2016).  
In the last forty years, the mortality rates for ovarian cancer have declined only slightly. In addition, in the last 
two decades, the two canonical types of drugs used to treat ovarian cancer (a cisplatin and a carboplatin, and a 
taxane) have not been replaced. Thus, many new therapies for the treatment of ovarian cancer are currently 
under study. Some of these involve Poly ADP ribose polymerase (PARP) inhibitors and molecules targeting 
the Her2 or PIP3/AKT/mTOR pathway. However, although the newest drugs such as bevacizumab (a 
humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody) or olaparib (a PARP-
1 inhibitor) delay cancer progression, they are not able to extend the lives of patients (Oza et al, 2015; Perren 
et al, 2011; Pujade-Lauraine et al, 2014). These observations show the need of a better understanding of the 
disease and its diagnosis, and the development of new therapeutic strategies. 
The tumor vasculature is structurally and functionally abnormal and is considered a hallmark of cancer. Thus, 
it is an attractive target for tumor therapy. However, as aforementioned, antiangiogenic treatments have failed 
to show significant response or to prolong survival in patients with solid tumors (Goel et al, 2012). This 
resistance of tumors to antiangiogenic therapies can be explained by the fact that tumor cells develop other 
mechanisms of vascularization that are not affected by the antiangiogenic compounds and produce several 
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proangiogenic factors that are not targeted by these drugs (Carmeliet and Jain, 2011). Although clinical data 
also suggest that anti-VEGF therapy cannot induce sustained shrinkage of human tumors, such as breast or 
colorectal tumors, patients who have received a combination of anti-VEGF and chemotherapeutics have 
shown to have a better response than to chemotherapy alone (Goel et al, 2012). This observation led to the 
hypothesis of “vascular normalization”, which states that the judicious use of an antiangiogenic therapy may 
reverse the abnormal structure and function of the pathological vasculature. This would result in an 
improvement in the delivery of the drugs and oxygen to the tumor cells (Jain, 2001).  
In the tumor vasculature, pericytes, which are the cells that provide support for endothelial cells of the vessels, 
are loosely attached or absent, and the basement membrane, if present, is often thick. As a result, tumor vessels 
are leaky, tortuous and dilated. This alteration in the vasculature contributes to tumor development and 
spreading by different mechanism. It also interferes with the delivery of therapeutics to solid tumors and the 
resulting hypoxia renders the tumor resistant to radiation and to several cytotoxic drugs (Jain, 2005). 
Interestingly, one of the features of vascular normalization includes vessel perivascular cell coverage. Several 
molecules are responsible for the recruitment of perivascular cells to vessels during angiogenesis, being 
PDGFB an essential player in this process. Angiogenic endothelial cells release PDGFB to chemoattract 
PDGF receptor-β+ pericytes to stabilize endothelial cell channels. Accordingly, periendothelial coverage 
deficiency after PDGFB ablation causes vessel leakage, tortuosity and bleeding, features similar to those of the 
tumor vasculature (Quaegebeur et al, 2010). In addition, PDGFB stimulates the proliferation of vascular 
smooth muscle cells and induces mural cell fate in undifferentiated mesenchymal cells (Gaengel et al, 2009). 
Pericytes play an important role in the maintenance of ovarian cancer vasculature (Lu et al, 2010; Lu et al, 
2008). Sood et al. (2008) demonstrated that PDGFB is predominantly expressed in endothelial and ovarian 
cancer cells, whereas PDGFRβ is present in pericyte-like cells (Lu et al, 2008).Several studies have found 
interesting results about the blockade of PDGF in tumor development and the effects of combined therapies 
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with VEGF inhibitors (Choi et al, 2015). However, no studies have analyzed PDGFB as a normalizing agent 
of the tumor vasculature. 
 Notch signaling is also an important player in angiogenesis. Beyond its role in regulating vessel branching 
(Hellstrom et al, 2007), the Notch system is involved in tumor development and metastasis (Li et al, 2013; 
Noguera-Troise et al, 2006; Pazos et al, 2017). In ovarian cancer, the DLL4 notch ligand has been suggested 
as a predictor of poor prognosis and its inhibition has been shown to potentiate the decrease in tumor growth 
caused by bevacizumab in an ovarian xenograft model (Hu et al, 2011). (Steg et al, 2011) demonstrated that 
the JAG1 notch ligand plays a role in tumor angiogenesis and chemoresistance. In addition, MK-0752, an 
inhibitor of Notch signaling, has been shown to induce a decrease in ovarian tumor growth, an effect 
significantly enhanced by cisplatin (Chen et al, 2016). In our lab, we have recently demonstrated that DAPT, 
an inhibitor of the Notch system, impairedalters the epithelial-to-mesenchymal transition induced by 
transforming growth factor beta (TGFβ) in ovarian cancer cell lines. Due to PDGFB function in vessel 
stabilisation and to the antitumor effect of Notch inhibition on ovarian cancer, in the present study, we sought 
to investigate the effect of DAPT treatment in combination with PDGFB in an ovarian cancer xenograft 
model. 
Chemical compounds 
Recombinant human PDGF-BB was kindly donated by Denver Farma S.A. (Buenos Aires, Argentina). 
Gamma-Secretase Inhibitor, DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)-S-phenylglycine t-butyl ester), 
Dimethyl sulfoxide (DMSO), NaCl, proteinase K, sodium dodecyl sulfate (SDS), bovine serum albumin 
(BSA), methanol, Na2HPO4, NaH2PO4, NP-40, glycerol and Tween-20 were from Sigma-Aldrich (St. Louis, 
MO, USA), and 3,3-diaminobenzidine (Aaboud and others) was from Roche Applied Science (Mannheim, 
Germany). The Fluorescein-labelled Lycopersicon (Tomato) Lectin was purchased from Vector Laboratories 
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(Burlingame, CA, USA). The details, suppliers and dilution of antibodies used in this study are reported in 
Table 1 (additional sheet). All other chemicals were of reagent grade and were obtained from standard 
commercial sources. 
In vivo xenograft model  
Human SKOV3 cells (1x106) suspended in 100 μL PBS were subcutaneously inoculated into two-month-old 
virgin female BALB/c mice (animal facility of the Instituto de Biología y Medicina Experimental, Buenos 
Aires, Argentina), nude mice (nu/nu, University of La Plata, Buenos Aires, Argentina). First, we performed a 
pilot experiment to examine the effect of recombinant PDGFB (rec-PDGFB) administered to mice bearing 
ovarian tumor xenografts. Once the tumors grew to an average size of 80mm2, mice were randomized in two 
groups: control and rec-PDGFB. The control group consisted of mice intravenously injected with saline, and 
the rec-PDGFB group included mice injected with rec-PDGFB (250 ng/mouse) for 4 consecutive days. After 4 
days of the last injection, all animals were weighed and euthanized, and the tumors were weighed and excised 
for western blot and immunohistochemistry techniques. Once that the rec-PDGFB dosis produced the 
desidered effect on the vasculature, we conducted an experiment that consisted of three groups of animals: 
control (injected with 20% DMSO solution), DAPT (injected with DAPT (0.1 mg/mouse)), and DAPT+rec-
PDGFB (injected with DAPT and rec-PDGFB (250 ng/mouse)) for 4 consecutive days. We followed the same 
procedure as described above. 
Vascular functionality assay 
In tumor-bearing mice of the control, DAPT, rec-PDGFB and DAPT+rec-PDGFB groups, we studied vascular 
functionality by using Fluorescein-labelled Lycopersicon lectin administration. Before the tumors were 
excised, the animals were perfused with a FITC-lectin solution (20 mg/mL) followed by 4% 
paraformaldehyde. The tumors were excised and fixed in cold 4% paraformaldehyde overnight. Tissues were 
embedded in OCT (Tissued-Tek OCT Compound) and frozen tumors were cut (15 μm) with a cryostat and, 
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finally the nuclei were counterstained with propidium iodide. Endogenous fluorescence was analyzed using a 
Nikon Eclipse E800 confocal Microscope. Images were taken with a Nikon DS-U1 camera with ACT-2U 
software.  
Western Blot analysis 
Tumors were suspended in 500 mL of lysis buffer (20 mM Tris–HCl pH 8, 137 mM NaCl, 1% Nonidet P-40, 
and 10% glycerol) supplemented with protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 0.025 mM 
N-CBZ-L-phenylalanine chloromethyl ketone, 0.025 mM N-p-tosyl-lysine chloromethyl ketone, and 0.025 
mM L-1-tosylamide-2-phenyl-ethylchloromethyl ketone), and phosphatase inhibitors (25 mM sodium fluoride, 
0.2 mM sodium orthovanadate, and 10 mM b-glycerophosphate) and homogenized using an Ultra-Turrax 
(IKA-Werke GmbH & Co., Staufen, Germany) homogenizer. The samples were centrifuged at 4-8ºC for 10 
min at 10 000 g and the resulting pellets were discarded. The protein concentration in the supernatant was 
measured by the Bradford assay. After boiling for 5 min, 20 mg of proteins was applied to an SDS–
polyacrylamide gel (10–15%) and electrophoresis was carried out at 25 mA for 1.5 h. The resolved proteins 
were transferred onto nitrocellulose membranes for 2 h. The blot was reincubated in a blocking buffer (5% 
nonfat milk, 0.05% Tween-20 in 20 mM TBS pH 8 for 1 h at room temperature, and then incubated with 
appropriate primary antibodies (Table 1) in 0.05% Tween-20 in 20 mM TBS pH 8 overnight at 4- 8ºC. The 
blots were then incubated with anti-rabbit or anti-mouse secondary antibodies conjugated with HRP (Table 1), 
detected by chemiluminescence and autoradiography using X-ray film. Protein loading was normalized by 
reprobing the same blots with antibody against β-Actin or GAPDH (Table 1). Protein expression was 
quantified by densitometric analysis using Scion Image Software for Windows (Scion Corporation, Worman’s 
Mill, CT, USA). 
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Immunohistochemistry 
Tumors were deparaffinized in xylene and rehydrated by graduated ethanol washes. Endogenous peroxidase 
activity was blocked with hydrogen peroxide in PBS, and nonspecific binding was blocked with 2% BSA for 
20 min at room temperature. The sections were incubated with appropriate primary antibodies (Table 1) 
overnight at 4-8 ºC. After washing, the slides were incubated with biotinylated anti-rabbit or anti-mouse IgG 
(Table 1) and after 30 min with avidin-biotinylated HRP complex (Vectastain ABC system; Vector 
Laboratories, Burlingame, CA, USA) for 30 min. Protein expression was visualised using (Aaboud and others) 
staining. The negative controls were obtained in the absence of primary antibody. The reaction was stopped 
using distilled water, stained with haematoxylin, and dehydrated before mounting with mounting medium 
(Canada Balsam Synthetic; Biopack, Argentina). The images were digitised using a camera (Nikon, Melville, 
NY, USA) mounted on a conventional light microscope (Nelipovich and others). Finally, the images were 
converted to a TIFF format (bi-level scale) for their analysis. Negative controls were obtained in the absence 
of primary antibodies. We determined the number of Ki67 and cleaved-caspase 3 positively stained nuclei. A 
total of 2000-3000 nuclei per experimental group were counted from five randomly selected fields per tumor 
and the number of positive cells were processed using Image J (Image Processing and Analysis in Java; 
National Institutes of Health, Bethesda, MD, USA; Rasband).  
To determine vascular stability, we measured the periendothelial area in tumor sections. For the 
quantification, the area occupied by vessels was manually limited, considering as such 
all immunopositive cells, isolated or in groups, with or without lumen. No immunostained vessel was excluded 
from the analysis. The total area of the image was measured and the periendothelial area was calculated 
dividing the absolute periendothelial area by the total image area. 
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Data analysis 
When the experiment involved two experimental groups, the variables were analyzed using Student’s t-test. 
For more than two groups, One-way analysis of variance (ANOVA) followed by Tukey test was used. Tumor 
growth curves were studied with Two-way repeated-measures ANOVA. Quantitative variables were expressed 
as means±standard error and, in all statistical tests, p<0.05 was considered statistically significant. GraphPad 
Prism (version 5.0, CA, USA) was used for statistical analysis. 
Results 
PDGFB administration increases periendothelial coverage of the tumor vasculature  
Based on the aberrant architecture of the tumor vasculature and the PDGFB role in the recruitment of smooth 
muscle cells for vascular maturation, we performed a pilot experiment to examine the effect of recombinant 
PDGFB (rec-PDGFB) administered to mice bearing ovarian tumor xenografts generated with the SKOV3 cell 
line. The mice treated with rec-PDGFB for four consecutive days showed no significant differences in tumor 
growth compared to control animals (Figure 1, Panel A). PDGFB administration caused no changes in the cell 
proliferation or apoptosis indices, as concluded from Ki67 staining analysis and cleaved-caspase 3 
quantification (Figure 2, Panels A and B, respectively). However, alpha smooth muscle actin (α-SMA) and 
PDGF receptor β (PDGFRβ) staining of tumor sections from mice treated with rec-PDGFB was significantly 
increased as compared to control animals (Figure 2, Panels C and D, respectively). The increased percentage 
of positive area for both proteins showed higher periendothelial coverage in the vasculature of these tumors. 
In our experimental model, this experiment demonstrated that the dose of rec-PDGFB chosen was efficient to 
chemoattract PDGFRβ+ pericytes to the tumor vasculature. In these conditions, PDGFB did not alter other 
tumor parameters. It is important to note that neither α-SMA nor PDGFRβ staining was detected in tumor 
cells or stroma, indicating no expression of either protein in non-vasculature-related cells (Figure 2, Panel D.).   
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Co-treatment with DAPT and PDGFB affects the structure and functionality of the tumor vasculature 
We analyzed the histological characteristics of the four experimental groups with H&E stained sections of 
each tumor (Figure 1, Panels B-E). In control conditions, tumors consisted of sheets of big and poorly 
differentiated cells. These sheets were randomly separated by thin fibro vascular septa. Cytologically, two 
different types of cells stand out: A group of cells with big and eosinophilic cytoplasm, loose nucleus with 
prominent nucleoli (“A” cells); and another group of smaller cells, with clear cytoplasm and condensed nuclei 
(“B” cells). Prominent mitotic figures are present almost exclusively in “A” cells. When treated with PDGFB, 
there is a clear increase in the proportion of “A” cells comprising approximately 90% of the whole tumor. 
Moreover, the mitotic figures observed in these cells suggest an increase in tumor cell proliferation in this 
treatment. Regarding fibro vascular septa, an expansion in number and diameter is seen at the expense of 
capillaries and fibroblasts, which means high tissue remodeling. DAPT treated tumors show a 50:50 
proportion of “A” and “B” cells which suggests a decrease in proliferating cell population. Also a slight 
increase in fibro vascular septa thickness can be observed, but still similar to control tumors.  
Interestingly, for the combination of PDGFB and DAPT, vast areas of necrosis and haemorrhage predominate 
mainly in the central areas of the tumoral mass. Again, cytologically, a 50:50 proportion of “A” and “B” cells 
are seen, and a regular number of medium septa turns up between them.  
We then examined the effect of DAPT and rec-PDGFB administration on the tumor vasculature. Mice bearing 
SKOV3 cell tumors were divided into three experimental groups, which received either no treatment (control 
group), DAPT (0.1 mg/animal) or DAPT and rec-PDGFB (DAPT+rec-PDGFB, 250 ng/mice). DAPT alone 
caused no changes in perivascular cell markers as α-SMA and PDGFRβ. However, the addition of rec-
PDGFB to the DAPT treatment significantly increased periendothelial coverage (Figure 3). We then studied 
whether this increase in vessel coverage had a correlation with a better vessel perfusion. To analyze vessel 
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functionality, we injected tumor-bearing mice with fluorescent tomato lectin to label perfused vessels. Control 
animals showed a mix of leaky (Figure 4, Panel A *) and defined vessels (Figure 4, panel A arrow). In the 
DAPT-treated mice, DAPT increased the diffusion of the fluorescence out of the vessels, and tumors showed 
higher permeability of the vasculature. Also, more vessel lumens were observed, perhaps due to an increase in 
vasculogenesis, and in addition, DAPT admimistration caused more vessel sprouting (Fig 4, Panel A, 
asterisk). The increased lectin diffusion observed in the DAPT-treated mice was not observed in the 
DAPT+rec-PDGFB group. The tumors of co-treated animals showed a lack of leaky vasculature and, similar 
to that observed in the rec-PDGFB tumors, the vessels looked well defined perhaps due to vasculature 
stabilisation. This showed a controlled regulation of the vasculature and an improved tumor vessel 
functionality in the co-treated mice compared to the control and DAPT groups. As mentioned, lectin perfusion 
in tumors of mice treated with rec-PDGFB (pilot experiment) showed a discrete and defined tumor 
vasculature (Figure 4, panel rec-PDGFB). The tumor oxygen supply was assessed by western blot of HIF-1α 
accumulation, which is precisely regulated by cellular oxygen concentration. DAPT administration showed a 
not statistically significant tendency to decrease HIF-1α levels (p=0.06). However, the co-treatment 
significantly reduced HIF-1α compared to control animals, indicating less hypoxic tumors (Figure 4, panel B). 
Co-treatment with DAPT and PDGFB alters tumor angiogenic factors 
VEGF-A is a key player in tumor angiogenesis and a strong vascular permeability factor (Chen et al, 2016; Dvorak, 
2002). In our model, DAPT treatment decreased tumor VEGF-A but caused no changes in its type 2 receptor, FLK-
1, or its phosphorylated state (p-FLK-1-Tyr1175) (Figure 5, panel A, C and D). Similar to DAPT 
monotherapy, DAPT+rec-PDGFB treatment decreased tumor VEGF-A compared to untreated animals. Again, 
the co-treatment caused no changes in FLK-1, but significantly decreased p-FLK-1-Tyr1175 compared to the 
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control and DAPT groups. These results suggest a lower activation of the VEGF pathway in the co-treated 
animals.  
The angiopoietin growth factor ligands (Ang 1-4) and their receptors (Tie 1 and 2) are essential in vascular 
maturation. Particularly, while Ang 1 stabilizes the quiescent endothelium, Ang 2 functions as a 
desestabilisation factor (Potente et al, 2011). When we examined the balance between Ang 1 and Ang 2 in the 
tumors, we observed that DAPT treatment caused no changes in the levels of either protein compared to 
control tumors (Figure 5, panel B and D). However, the co-treatment with DAPT+rec-PDGFB significantly 
increased Ang 1 and significantly decreased Ang 2, resulting in a higher Ang 1/Ang 2 ratio compared to the 
control or DAPT-treated animals (Figure 5, panel F). This showed that the DAPT+rec-PDGFB treatment 
induced a balance of Angiopoietins that favoured tumor vascular stabilisation.  
Co-treatment with DAPT and PDGFB decreases ovarian tumor growth  
Because PDGFB improved tumor vessel function in our experimental model, we sought to analyze whether 
DAPT treatment had an effect on this parameter, and if so, whether PDGFB caused any change on it. When 
the animals were treated with DAPT alone, tumor growth tended to decrease as early as from day 2 of 
administration, but the difference in tumor size was not statistically different compared to the control group 
until day 6 of the experiment (Figure 6, panel A). The co-administration of PDGFB and DAPT significantly 
reduced the tumor growth rate (nearly blocked the growth) compared to the control and DAPT groups and, 
during the whole treatment, the tumor size of the co-treated group remained close to the initial size (Figure 6, 
panel A). Besides, as early as day 2 of the co-treatment, the tumor size started to be significantly lower than 
that of DAPT tumors, which was the same until the end of the experiment (Figure 6, panel A, day 2) and had 
no differences with control tumors. In addition, the difference between DAPT and DAPT+rec-PDGFB 
treatment increased in significance throughout the whole treatment. Similarly, DAPT monotherapy had no 
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effect on tumor weight, while the co-treatment significantly decreased the values of this parameter (control: 
1.54±0.09; DAPT: 1.55±0.11; DAPT+rec-PDGFB: 0.90±0.18, (gr) p<0.05). No signs of toxicity were 
observed and animal weight remained stable during the course of both treatments (data not shown). 
We next evaluated tumor cell proliferation by analysing Ki67 staining by immunohistochemistry and PCNA 
expression by western blot. Both the DAPT and DAPT+rec-PDGFB treatments decreased tumor Ki67 
expression compared to the control group, showing no differences between each other (Figure 3, panel Ki67). 
Similarly, the co-treatment decreased PCNA expression compared to the control group, but DAPT 
monotherapy caused no changes in this marker (Figure 6, panel B). This could be due to the different time 
points of expression of each protein during the cell cycle.   
The DAPT and DAPT+ rec-PDGFB treatments also significantly decreased the phospho-AKT/AKT ratio 
(p<0.01 and p<0.001 vs control, respectively), showing no differences between each other (control: 
0.81±0.02; DAPT: 0.45±0.05; DAPT+rec-PDGFB: 0.27±0.047, densitometric units) (Figure 6, Panel C). 
However, the co-treatment significantly increased the protein levels of phosphatase and tensin homolog 
(PTEN) (control: 0.39±0.03: DAPT+rec-PDGFB: 0.68±0.07, p<0.01) while DAPT monotherapy induced no 
changes in this parameter (DAPT: 0.40±0.03) (Figure 6, panel D).  
 
The DAPT treatment tended to increase the number of tumor apoptotic cells, as revealed by cleaved caspase 3 
immunostaining (Figure 6, panel D). The addition of PDGFB made the trend significant, increasing tumor cell 
apoptosis in co-treated mice as compared to untreated ones. 
Discussion 
The novel finding of this study is that a dose of DAPT, a gamma-secretase inhibitor, which was ineffective to 
reduce ovarian tumor growth in mice, showed anticancer activity when co-administered with PDGFB. We 
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also demonstrated that the administration of PDGFB alone normalized the tumor vasculature by increasing 
periendothelial coverage and vascular functionality. Interestingly, in the presence of DAPT, PDGFB still 
altered the tumor milieu by improving vessel functionality and oxygenation. We also observed that the 
animals co-treated with DAPT and PDGFB were more sensitive to the DAPT anticancer effect than those 
which received DAPT alone. This sensitization could be due, at least in part, to an improvement of the tumor 
vasculature produced by PDGFB, which facilitates the delivery of the antitumor drug to the tumor. 
The Notch and PDGF systems play pivotal roles in angiogenesis, and the Notch system has also been involved 
in cancer biology. Of the PDGF family members, PDGFB is involved in the recruitment of perivascular cells 
to vessels during angiogenesis. In this process, angiogenic endothelial cells release PDGFB to chemoattract 
PDGF receptor-β+ pericytes. In this way, PDGFB is responsible for the stabilisation of the vasculature 
(Quaegebeur et al, 2010). Notch signaling is involved in vessel branching, regulating proliferation and 
migration of the tip and stalk cells. This system restricts branching by the downregulation of VEGF receptor 2 
and generates perfused vessels (Phng and Gerhardt, 2009). Notch also participates in vessel maturation by 
upregulating PDGF receptor-β in Notch-positive mural cells (Benedito et al, 2009).  
In search of new therapeutic strategies to improve ovarian cancer treatment, in the present study, we first 
evaluated the effect of PDGFB on the tumor vasculature, based on its role in physiological angiogenesis. As 
mentioned, the tumor vasculature has an aberrant structure, which causes high hypoxia and low pH in tumors, 
generating a promalignant microenvironment. These abnormalities facilitate the selection and dissemination 
of the most malignant cancer cells through the leaky vessels, preventing the correct delivery of anticancer 
drugs, and thus causing poor responses to therapies (Goel et al, 2012). In our experimental model, we 
observed that PDGFB increased the periendothelial area in tumors, as shown in the analysis of the expression 
of α-SMA and PDGFR-β. We did not observe PDGFR-β protein expression in tumor cells not related to the 
vasculature, and the dose of PDGFB used showed no effect on tumor cell proliferation or apoptosis. This was 
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in accordance with the lack of differences observed in the tumor growth curves between control and PDGFB-
treated animals. Few reports have described the expression of PDGFR-β in ovarian tumor cells. (Apte et al, 
2004) showed that SKOV3ip1, a variant of SKOV3 cells, stained weakly for PDGFR-β when implanted 
orthotopically in nude mice. This is similar to our results where we detected no staining for this receptor in 
tumor or stromal cells, unlike that observed in those stained with α-SMA. In the present study, we also found 
an improvement in vessel functionality and a reduction in the chaotic vascular structure by lectin perfusion in 
tumors of animals treated with PDGFB. The lack of effect of PDGFB on tumor growth is in agreement with 
the results of Chunhua L et al. 2010, who targeted pericytes with a PDGFB aptamer in human ovarian 
carcinoma models and observed no changes in tumor growth (Lu et al, 2010). Tumor vessel normalization 
often does not affect the size of primary tumors, but its benefits are related to a reduction of metastasis and to 
an improved drug delivery and efficiency of the chemotherapy (Carmeliet and Jain, 2011). The effect of 
PDGFB treatment could be an interesting strategy to be further studied because of the reported ability of 
vascular smooth muscle cells to inhibit endothelial cell proliferation. The increase in pericyte content in the 
tumor microenvironment inhibits the growth of angiogenesis-dependent tumors (McCarty et al, 2007).  
Several lines of evidence have demonstrated the involvement of the Notch system in ovarian cancer biology. 
Some reports have shown an increased content of Dll4 and Jagged1 ligands as well as of Notch1 and Notch3 
receptors, in ovarian tumor tissues (Hu et al, 2014; Hu et al, 2011; Jung et al, 2010; Xie et al, 2017). 
Moreover, in 2011, the Cancer Genome Atlas published a study performed in 316 cases of High Grade Serous 
Ovarian Cancer, 22% of which showed an alteration in the Notch signaling pathway among other deregulated 
signaling pathways (Bell, 2011). In addition, in a granulosa tumor cell line representative of the adult form of 
Granulosa Cell Tumors, we have previously demonstrated that JAGGED1, DLL4, NOTCH1, and NOTCH4 
are highly expressed in tumor cells as compared to that observed in granulosa-lutein cells obtained from 
patients undergoing assisted reproductive techniques (Pazos et al, 2017). Notch signaling inhibitors have been 
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developed in recent years, and some are in current clinical trials. Gamma-secretase inhibitors, which target all 
Notch receptors, are the most widely studied agents. Different gamma-secretase inhibitors have shown 
promising antitumor activity in early-phase clinical trials in advanced solid tumors and a correlation has been 
found between the expression of Notch members and the response to these therapies (Xie et al, 2017).  
In the present study, we also detected an interesting antiproliferative and proapoptotic effect of the gamma-
secretase inhibitor DAPT in an ovarian cancer xenograft model. It has been demonstrated that the inhibition of 
the Notch ligand JAGGED1 causes anti-angiogenic effects in ovarian tumor models and significantly 
decreases cell viability (Steg et al, 2011). Similar results have been obtained for DLL4, where the inhibition 
of this protein in tumor and tumor-associated endothelial cells has been shown to inhibit cell growth and 
angiogenesis simultaneously with an increase in hypoxia (Hu et al, 2011). In our experimental model, the 
blockade of the Notch system by means of DAPT showed a tendency to decrease tumor growth compared to 
control tumors. The complete blockade of the system independently of the type of ligand and receptor caused 
no alterations in most of the angiogenic parameters analyzed but there was a clear action of the inhibitor in 
vascular functionality and structure. This was easily observed in our experiment with tomato-lectin and the 
images of the morphology of the tumor vasculature shown in photographs of the tumors treated with DAPT. 
Both images showed numerous and disorganised vessels, which seem highly permeable as denoted by lectin 
pictures where diffused vessel walls due to lectin extravasation were observed. The high number of vessels 
and the chaotic structure observed in the pictures of DAPT-treated tumors compared to control tumors agree 
with the experiments in mouse retina performed by Hellstrom et al. (2007). These authors described an 
increase in vascular density and vascular abnormalities after DAPT administration. One of the first reports of 
Notch involvement in tumor angiogenesis was performed by Noguera-Troise et al., who defined DLL4 
function in murine tumor models (Noguera-Troise et al, 2006). By the blockade of DLL4, these authors 
showed a decrease in tumor growth and a highly branched vasculature full of sprouts and filopodia. However, 
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they found an increase in hypoxia in tumors lacking DLL4 activity compared to control tumors, indicating that 
the vasculature was not efficiently delivering oxygen to the surrounding tumor. In our experiments, DAPT 
administration led to a slight but not significant decrease in HIF-1α levels. This suggests that although we 
observed more vessels in lectin images obtained from DAPT-treated mice, this vasculature could be non-
functional, in agreement with previous reports. In our DAPT-treated tumors, HIF-1α levels were similar to 
those of control tumors, probably due to the short treatment period or the dose of DAPT administered. In 
addition, DAPT inhibits not only the activation of the system through DLL4 (directly involved in 
angiogenesis), but also the complete activation of the Notch system. This could dilute the effect of the 
inhibition of the Notch ligands and receptors strictly involved in angiogenesis with other members of the 
system that do not participate in the process in a predominant manner. Interestingly, the addition of rec-
PDGFB to the DAPT treatment decreased tumor hypoxia (HIF-1α levels). This effect was equally observable 
in lectin studies, where the images of lectin-perfused tumors from animals treated with DAPT+rec-PDGFB 
showed that the number of vessels was similar to that in control tumors. However, the tumor vasculature of 
the co-treated animals was more defined as a result of the low permeability and also regularly distributed 
when compared to control and DAPT-treated tumors. At macroscopic and functional levels, these results 
showed the normalizing effect of PDFGB on tumor vasculature. The vascular normalization was corroborated 
with the pronounced increase in α-SMA and PDGFR-β staining in tumor sections of DAPT+rec-PDGFB-
treated mice. Another evidence of the normalized vasculature in our model was the effect of the co-treatment 
on the VEGF and Angiopoietin systems. The fact that the administration of DAPT or DAPT+rec-PDGFB 
decreased tumor VEGF levels is important because, for the normal development and function of blood 
vessels, VEGF must be tightly regulated in endothelial cells. It is very well known that the production of 
VEGF and other growth factors by the tumor results in the 'angiogenic switch', where new structurally and 
functionally abnormal vasculature is formed in and around the tumor (Carmeliet, 2005). Thus, when designing 
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and testing a new and potential therapy for ovarian cancer, it is important to consider the action of the therapy 
in the tumor and serum VEGF levels. In the vasculature, VEGF is a potent and powerful vascular 
permeabilising agent and a potent vasodilator, features of the tumor vasculature which are due to, among other 
causes, the high levels of tumor and serum VEGF (Glass et al, 2006). Sixteen studies with 1111 patients 
analyzed performed in 2011 demonstrated that, in patients with early-stage ovarian cancer, the overexpression 
of VEGF in primary tumor and serum is associated with poor progression-free survival and overall survival 
(Yu et al, 2013). 
Another interesting and beneficial effect of the treatment with DAPT and rec-PDGFB was the alteration of 
tumor Angiopoietins 1 and 2 (ANG1 and ANG2). In angiogenesis, ANG1 functions as an agonist of the 
receptor TIE2 and ANG2 functions as a competitive ANG1 antagonist. In our experimental model, the co-
treatment increased tumor ANG1 and decreased tumor ANG2. It is well known that ANG1 stimulates mural 
coverage and basement membrane deposition, thereby promoting vessel tightness (Augustin et al, 2009). 
Therefore, with DAPT+rec-PDGFB treatment, the increase in tumor ANG1 could be cooperating in the 
vasculature normalization. Regarding ANG2, beyond its role as a vascular destabilization factor, it has been 
identified as a tumor biomarker of tumor progression in a number of different tumors. Hence, the decrease in 
the levels of this protein in our model is also a beneficial effect of our antitumor therapy. Although the exact 
roles of ANG1 and ANG2 in the tumor vasculature are not clear, the change in the balance between 
angiopoietins (high ANG2 relative to ANG1) may promote the growth and vascularization of tumors (Holash 
et al, 1999). Therefore, therapies that reverse this ratio may be useful to inhibit undesirable angiogenesis. 
Moreover, the benefit of diminishing both VEGF and ANG2 has also been described by Peterson et al. (2016) 
in a glioblastoma model where a dual therapy inhibiting both factors enhanced the morphological 
normalization of the vessels, in agreement with the modulation of vascular function. 
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AKT is a protein known to play a central role in many cellular processes that, when deregulated, can 
contribute to the development or progression of cancer. In ovarian cancer, the PI3K/AKT/mTOR pathway is 
frequently deregulated and has been identified as the pathway most commonly altered in this type of cancer 
(Huang et al, 2011). It is also known that VEGF exhibits multiple biological effects on endothelial cells that 
are mediated by VEGFR2-PI3K-AKT (Shiojima and Walsh, 2002). The DAPT treatment decreased tumor 
AKT pathway activation, an effect enhanced by the co-treatment, which led to an increase in the levels of 
PTEN. The less active state of this pathway in tumors could be due to different reasons, including a decrease 
in FLK-1 receptor phosphorylation and a decrease in tumor cell proliferation. Besides, DAPT administration 
increased the number of apoptotic cells, an effect intensified by the co-treatment with PDGFB. These 
molecular effects were in accordance with the action of the treatments on the tumor size. 
Finally, among the Notch actions on tumor cells, several reports describe the consequences of blocking the 
Notch system on angiogenesis, suggesting a synergism effect of inhibition of tumor angiogenesis and tumor 
cell proliferation. Although Notch signaling is very context-dependent, in ovarian cancer it has been 
unequivocally demonstrated to be an oncogenic pathway (Nowell and Radtke, 2017). In the present study, we 
suggest the use of the gamma-secretase inhibitor DAPT as an antitumor therapy for ovarian cancer and the co-
administration of the recombinant factor PDGFB as a tumor vasculature normalizing agent. Due to the 
promising observations in this work, our future studies will be focused in determining a suitable 
administration protocol and the vascular normalization window for this potential therapeutic strategy.  
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LEGENDS 
Figure 1. PDGFB treated tumour growth and inmunohistochemical analysis of ovarian xenograft 
tumours.  
Panel A. SKOV3 cells were inoculated in female nude mice. When tumours were palpable the animals 
received rec-PDGFB as treatment or saline solution (control) as described in Material and methods section. 
Tumour size were measured both groups. The variable was analyzed using Student’s t-test. No statistical 
difference was found between groups. 
Panels B-E show H&E stained sections of each tumour belonging to all experimental groups (control, rec-
PDGFB, DAPT and DAPY+rec-PDGFB). Scale bars: 20 µm in 10x magnification pictures and 50 µm in 40 x 
magnification insets. 
 
Figure 2. Immunohistochemistry analysis of factors related to proliferation, apoptosis and angiogenesis 
in control and PDGFB treated tumours. 
Ki67 proliferation marker immunostaining of tumour sections (Panel A) and  cleaved caspase-3 staining 
(Panel B). Staining is observed in cell nuclei for both proteins and quantification histogram for each shows the 
ratio between the number of positively stained cell nuclei and the total number of the nucleous.. Panel C 
shows alpha smooth muscle actin (αSMA) and panel B depicts PDGF receptor β staining (PDGFRβ). The 
quantification histograms represent the percentage of positively stained area of the tumour sections.  Asterisk 
indicates significant differences between groups. Unpaired t test.  
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Figure 3. Immunohistochemistry analysis of Ki67, cleaved caspase-3, αSMA and PDGFRβ in ovarian 
xenograft tumours.  
Ki67 and cleaved caspase-3 quantification are expressed as the ratio between the number of positively stained 
cell nuclei and the total number of the nucleous. Staining is observed in cell nuclei for both proteins. αSMA 
and PDGFRβ quantification histograms show the percentage of positively stained area of the tumour sections.  
Panel A shows αSMA staining and Panel B depicts PDGFRβ of control, DAPT and DAPT±rec-PDGFB 
treated tumours. Quantification histograms show percentage of positively stained area of the tumour sections. 
Different letters indicate significant differences between groups. One way ANOVA followed by tukey 
multiple comparisions test. 
 
Figure 4. Analysis of vessel funcionality with fluorescent tomato lectin staining and HIF-1α levels. 
Panel A shows fluorecent tomato lectin staining of control, DAPT, rec-PDGFB and DAPT±rec-PDGFB 
treated tumours. In control, rec-PDGFB and co-treated tumour sections, asterisk indicates leaky vessels and 
arrow shows defined vessels.  In DAPT tumour section, asterisk indicate lectin extravasation and arrow 
indicates vessel lumens and vessel sprouting. Panel B depicts quantification histogram of HIF-1α levels 
determined by western blot in tumour protein extracts and expressed as densitometric units. a vs b means 
significant differences with p<0.05. Scale Bar: 50 µm. 
 
Figure 5. Protein levels of angiogenic factors in ovarian xenograft tumours. 
Angiogenic factors levels were determined by western blot in ovarian xenograft tumours protein extracts and 
different panels show quantification histograms with densitometric units and expresed as mean±SEM. 
Different letters indicate significant differences between treatments. a vs b p<0.05. 
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Figure 6: Ovarian xenograft tumour growth of DAPT and PDGFB co-treated animals and levels of 
related proteins. 
Panel A. SKOV3 cells were inoculated in female nude mice. When tumours were palpable the animals 
received the treatments (control, DAPT, rec-PDGFB and DAPT+rec-PDGFB). Tumour size were measured in 
the three groups. The data was analyzed with Two-way repeated-measures ANOVA. Significances were 
analyzed day by day and are shown as follows: *DAPT vs DAPT+rec-PDGFB; ** control vs DAPT+rec-
PDGFB; a vs b, control vs DAPT p<0.05; a vs c, control vs DAPT p<0.001; b vs c, control vs DAPT, p<0.01. 
The other panels show protein levels of PCNA, phospho-AKT/AKT ration and PTEN in tumour protein 
extracts determined by western blot. a vs b, p<0.05 and a vs c, p<0.01. 
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Table 1. List of antibodies and their dilutions used for the different techniques.  
Antibody Target Host/type Catalog Nº             Supplier Technique Dilution 
Primary Antibodies      
AKT Rabbit Polyclonal 9272 Cell Signaling Technologya Western 
Blot 
1/5000 
Phospho-AKT (ser 473) Rabbit Polyclonal sc-7985 Santa Cruz Biotechnology, 
Inc.b 
Western 
Blot 
1/400 
PTEN Rabbit 
Monoclonal 
MAB4037  Milliporec Western 
Blot 
1/500 
PCNA (Fl-261) Rabbit Polyclonal Sc-7907 Santa Cruz Biotechnology, 
Inc.b 
Western 
Blot 
1/500 
VEGF Mouse 
Monoclonal  
Sc-7269 Santa Cruz Biotechnology, 
Inc.b 
Western 
Blot 
1/100  
VEGFR2/ FLK-1 /KDR Rabbit 
Monoclonal 
2479 Cell Signaling Technologya Western 
Blot 
1/500 
5%BSA 
Phospho-VEGFR2  
(Tyr1175)  
Rabbit 
Monoclonal 
2478 Cell Signaling Technologya Western 
Blot 
1/500 
5%BSA 
Angiopoietin-1 Rabbit Polyclonal 10516 Milliporec Western 
Blot 
1/500 
Angiopoietin-2 
 
Rabbit Polyclonal 
 
180820 
 
Abcamf 
 
Western 
Blot 
 
1/500 
HIF-1α Mouse 
Monoclonal 
MAB1536 R&D Systemsd Western 
Blot 
1/500 
β-Actin Rabbit Polyclonal sc-1616 Santa Cruz Biotechnology, 
Inc.b 
Western 
Blot 
1/10000 
GAPDH Rabbit 
Monoclonal 
2118 Cell Signaling Technologya Western 
Blot 
1/10000  
Ki67 Rabbit Polyclonal Ab15580 Abcamf IHC 1/500 
Cleaved Caspase 3  
Rabbit Polyclonal Cp229 Biocare Medicale IHC 1/100 
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α-SMA Mouse Polyclonal ab18147 Abcamf IHC 1/100 
PDRFRβ Rabbit Polyclonal Sc-432 Santa Cruz Biotechnology, 
Inc.b 
IHC 1/200 
Secondary Antibodies      
Rabbit IgG 
(Biotinylated) 
Goat Polyclonal BA-1000 Vector Laboratoriesg IHC 1/400 
Mouse IgG 
(Biotinylated) 
Goat Polyclonal BA-9200 Vector Laboratoriesg IHC 1/400 
Rabbit IgG (conjugated 
to HRP) 
 
Goat Polyclonal 
 
A-9414 
 
Sigma-Aldrichh 
 
Western 
Blot 
 
1/1000 
Mouse IgG (conjugated 
to HRP) 
Goat Polyclonal HAF007 R&D Systemsd Western 
Blot 
1/1000 
 
aCell Signaling Technology (Beverly, MA, USA). 
bSanta Cruz Biotechnology, Inc., Santa Cruz, CA, USA 
cMillipore.  
dR&D Systems  (MN,USA) 
eBiocare Medical (Concord, CA, USA). 
fAbcam (Cambridge, Massachusetts, USA). 
gVector Laboratories, (Burlingame, CA, USA). 
hSigma-Aldrich (St. Louis, MO, USA). 
IHC, immunohistochemistry; Ig, immunoglobulin; HRP, horse radish peroxidase. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
